drugset / Trial / NCT05645692
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Timeline
- Start
- 2023-04-13
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Tobemstomig | Monoclonal antibody | 600 mg | Intravenous |